Evidence map›Paper›PMID 41722042›Full record

ArticleAmerican journal of physiology. Cell physiology2026

High-fat diet and obesity each increase tumor cell proliferation and muscle wasting in experimental cancer cachexia.

Brittany R Counts, Andrea Bonetto, Ho Lam Chan, Ernie D Au, Yanlin Jiang, Marion E Couch, Denis C Guttridge, Michael C Ostrowski, Leonidas G Koniaris, Teresa A Zimmers

Abstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Brittany R CountsDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, United States.ORCID 0000-0002-4525-9820
Andrea BonettoDepartment of Surgery, University of Miami Miller School of Medicine, Miami, Florida, United States.ORCID 0000-0002-3235-1871
Ho Lam ChanDepartment of Surgery, University of Miami Miller School of Medicine, Miami, Florida, United States.
Ernie D AuDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, United States.
Yanlin JiangDepartment of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, United States.ORCID 0000-0003-1235-2671
Marion E CouchDepartment of Otolaryngology-Head & Neck Surgery, Indiana University School of Medicine, Indianapolis, Indiana, United States.
Denis C GuttridgeDepartment of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, United States.
Michael C OstrowskiDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, United States.
Leonidas G KoniarisDepartment of Surgery, Oregon Health & Science University, Portland, Oregon, United States.
Teresa A ZimmersDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, United States.ORCID 0000-0001-7872-0540

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Grace B Gill · 1997 to 2026
$60.5M
The role of the macroenvironment in pancreatic cancer-induced cachexiaP01CA236778 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI NEELON, BRIAN · 2021 to 2025
$9.7M
Integrated Training in Quantitative and Experimental Cancer Systems BiologyT32CA254888 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Sudarshan Anand, LISA M COUSSENS · 2021 to 2026
$2.2M
PQ6: Lipocalin-2 as a therapeutic target for prevention of cancer cachexiaR01CA257452 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ZIMMERS, TERESA A · 2021 to 2025
$1.9M
Manipulation of STAT3 Signaling for Muscle Preservation in Cancer CachexiaR01CA122596 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ZIMMERS, TERESA A · 2010 to 2015
$1.6M
EGFR therapies for fatty liver surgeryR01DK096167 · NIDDK · THOMAS JEFFERSON UNIVERSITY · PI KONIARIS, LEONIDAS G. · 2012 to 2014
$1.0M
CSRD VA I01 CX002046HHS | NIH | National Cancer Institute (NCI) P01CA236778HHS | NIH | National Cancer Institute (NCI) P30CA069533HHS | NIH | National Cancer Institute (NCI) R01CA122596HHS | NIH | National Cancer Institute (NCI) T32CA254888HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK096167NCI NIH HHS P01 CA236778NCI NIH HHS R01 CA122596NCI NIH HHS R01 CA257452Pennsylvania Department of Health (DOH) 080-37038-AI0801
6 · The paper itself

Abstract

High-fat diet (HFD) and associated obesity are suggested to predispose to cancer development, complicate cancer treatment, and accelerate mortality. Paradoxically, obese patients with lung cancer are reported to live longer, suggesting that high body mass is protective. Given that cachexia-tumor-induced weight loss with adipose and muscle wasting-is prevalent in lung cancer, we speculated that patients with obesity might survive longer due to the protective effect of larger tissue reservoirs, slowing time to fatal wasting. Thus, we modeled this condition using lean and high-fat diet (HFD)-induced obese mice with Lewis lung carcinoma (LLC) tumors versus nontumor-bearing controls. We also assessed the effects of feeding HFD to lean mice with and without LLC tumors. HFD and obese-HFD mice without tumors gained weight over the study, with obese-HFD mice exhibiting low muscle mass with obesity at endpoint. Low-fat diet (LFD)-fed lean mice with LLC tumors (LFD-LLC) showed no change in total body weight, but exhibited reduced skeletal muscle, heart, and fat pad mass along with hepatosplenomegaly at endpoint. HFD and pre-existing obesity both modified the response to Lewis lung carcinoma (LLC) tumors. HFD did not affect tumor-induced weight loss, fat loss, or tumor burden, but worsened loss of gastrocnemius, tibialis anterior, and heart muscle, prevented hepatosplenomegaly, and enhanced tumor cell proliferation and expression of the cachexia-inducing cytokine, interleukin-6 (IL-6). Obese-HFD mice showed greater tumor burden versus LFD and the worst cachexia phenotypes, including greater weight loss and muscle loss than HFD or LFD. This worsened cachexia was associated with increased blood-borne inflammatory cytokines, increased phosphorylated STAT3 in muscle, and increased IL-6 expression in muscle, spleen, and tumor. Obese-HFD was associated with the highest rate of tumor cell proliferation in vivo, and serum from obese HFD mice increased LLC cell proliferation in vitro. Thus, HFD and pre-existing obesity each separately enhance inflammation, cachexia, and tumor growth. These distinct contributions of HFD and chronic adiposity are potential therapeutic targets to slow cachexia and tumor growth in cancer.

Indexed as

CachexiaCarcinoma, Lewis LungCell ProliferationDiet, High-FatMuscle, SkeletalMuscular AtrophyObesityAnimalsDisease Models, AnimalInterleukin-6MaleMiceMice, Inbred C57BLInterleukin-6cancer cachexiahigh-fat dietinterleukin-6obesitysarcopenia

Identifiers

PMID41722042
PMCPMC13053052

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.